4 Stocks Pushing The Drugs Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 57 points (-0.4%) at 13,961 as of Wednesday, Feb. 13, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,624 issues advancing vs. 1,238 declining with 155 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is unchanged. A company within the industry that increased today was Sanofi ( SNY), up 0.9%.

TheStreet Ratings group would like to highlight 4 stocks pushing the industry lower today:

4. Seattle Genetics ( SGEN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Seattle Genetics is down $1.20 (-4.1%) to $28.04 on heavy volume Thus far, 982,906 shares of Seattle Genetics exchanged hands as compared to its average daily volume of 754,800 shares. The stock has ranged in price between $28.01-$29.29 after having opened the day at $28.37 as compared to the previous trading day's close of $29.24.

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Seattle Genetics has a market cap of $3.5 billion and is part of the health care sector. Shares are up 27.1% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Seattle Genetics a buy, 2 analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Seattle Genetics as a sell. The area that we feel has been the company's primary weakness has been its feeble growth in its earnings per share. Get the full Seattle Genetics Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Biotech Leaders Join Corporate Chorus Angry Over Trump's DACA Move

Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers

Biotech Movers: Clovis, Seattle Genetics, Rigel

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct

Analysts' Actions -- Costco, J.C. Penney, Cisco, TherapeuticsMD and More